125 related articles for article (PubMed ID: 19141763)
1. Thyroid-stimulating hormone-receptor antibody and thyroid hormone concentrations in smokers vs nonsmokers with Graves disease treated with carbimazole.
Nyirenda MJ; Taylor PN; Stoddart M; Beckett GJ; Toft AD
JAMA; 2009 Jan; 301(2):162-4. PubMed ID: 19141763
[No Abstract] [Full Text] [Related]
2. Carbimazole treatment in smokers vs nonsmokers with Graves disease.
Shin JI; Lee JS
JAMA; 2009 May; 301(19):1988-9; author reply 1989. PubMed ID: 19454634
[No Abstract] [Full Text] [Related]
3. Calm Before the Storm: Marine-Lenhart Syndrome After Hashimoto Thyroiditis.
Chen X; Cai HY; Ong SS; Kiew JJ; Teo DB
Am J Med; 2021 Nov; 134(11):e557-e558. PubMed ID: 34214461
[No Abstract] [Full Text] [Related]
4. The response in toxic diffuse goitre to a short course of antithyroid therapy.
Clark F; Hall R; Anderson J; Farmer FT
Clin Sci; 1970 Jul; 39(1):2P. PubMed ID: 4194428
[No Abstract] [Full Text] [Related]
5. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
6. Development of hypothyroidism with thyroid stimulation blocking antibody long after treatment with antithyroid drugs in a patient with hyperthyroid Graves' disease: a case report.
Kasuga Y; Sugenoya A; Kobayashi S; Shimizu T; Onuma H; Shingu K; Asanuma K; Hama Y; Iida F
Endocr J; 1993 Apr; 40(2):227-30. PubMed ID: 7524926
[TBL] [Abstract][Full Text] [Related]
7. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
8. Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment.
Maugendre D; Gatel A; Campion L; Massart C; Guilhem I; Lorcy Y; Lescouarch J; Herry JY; Allannic H
Clin Endocrinol (Oxf); 1999 Jan; 50(1):127-32. PubMed ID: 10341866
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease, thymus enlargement, and hypercalcemia.
Giovanella L; Suriano S; Ceriani L
N Engl J Med; 2008 Mar; 358(10):1078-9. PubMed ID: 18322294
[No Abstract] [Full Text] [Related]
10. Thyroid stimulating immunoglobulin bioactivity during carbimazole therapy as measured by the cytochemical bioassay.
Prentice MG; Rayman GA; Alaghband-Zadeh J; Wise PH
J Endocrinol Invest; 1987 Oct; 10(5):483-9. PubMed ID: 2892877
[TBL] [Abstract][Full Text] [Related]
11. Outcome of treatment of hyperthyroidism.
Bringmann IM; van Leeuwen BL; Hennemann G; Beckett GJ; Toft AD
J Endocrinol Invest; 1999 Apr; 22(4):250-6. PubMed ID: 10342357
[TBL] [Abstract][Full Text] [Related]
12. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.
Abbara A; Clarke SA; Brewster R; Simonnard A; Eng PC; Phylactou M; Papadopoulou D; Izzi-Engbeaya C; Sam AH; Wernig F; Jonauskyte E; Comninos AN; Meeran K; Kelsey TW; Dhillo WS
Front Endocrinol (Lausanne); 2020; 11():286. PubMed ID: 32477269
[No Abstract] [Full Text] [Related]
14. Which antithyroid drug regimen in paediatric Graves' disease?
Schenk D; Donaldson M; Cheetham T
Clin Endocrinol (Oxf); 2012 Dec; 77(6):806-7. PubMed ID: 22816522
[No Abstract] [Full Text] [Related]
15. Immunosuppressive effects of antithyroid drugs.
Ratanachaiyavong S; McGregor AM
Clin Endocrinol Metab; 1985 May; 14(2):449-66. PubMed ID: 2415278
[No Abstract] [Full Text] [Related]
16. [Serum thyroid hormones and TSH response to TRH during treatment of Graves' disease by carbimazole (author's transl)].
Lorcy Y; Heim J; Auvray E; Allannic H
Ann Endocrinol (Paris); 1979; 40(4):441-2. PubMed ID: 117739
[TBL] [Abstract][Full Text] [Related]
17. Iodine distribution in thyroid tissue taken from hyperthyroid patients treated with Lugol's solution or carbimazole.
Etling N
Rev Eur Etud Clin Biol; 1971; 16(7):662-7. PubMed ID: 4107371
[No Abstract] [Full Text] [Related]
18. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
19. Rapid preoperative blockage of thyroid hormone production / secretion in patients with Graves' disease.
Fischli S; Lucchini B; Müller W; Slahor L; Henzen C
Swiss Med Wkly; 2016; 146():w14243. PubMed ID: 26765838
[TBL] [Abstract][Full Text] [Related]
20. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
